On June 24, 2012, the U.S. Supreme Court handed down its decision in Mutual Pharmaceutical Co. Inc. v. Bartlett, 570 U.S. ____ (2013), finding that design-defect claims against generic drug companies are pre-empted where...more
7/8/2013
/ Design Defects ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Labeling ,
Mutual Pharmaceuticals v Bartlett ,
Pharmaceutical Industry ,
PLIVA v Mensing ,
Preemption ,
Prescription Drugs ,
SCOTUS